Published online before print December 6, 2004, doi: 10.1161/01.CIR.0000150400.15354.7D
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:3822-3829.)
© 2004 American Heart Association, Inc.
Transplantation |
Anti–Transforming Growth Factor Antibody at Low but Not High Doses Limits Cyclosporine-Mediated Nephrotoxicity Without Altering Rat Cardiac Allograft Survival
Potential of Therapeutic Applications
From the Division of Nephrology (A.K.K., M.S.P.), and Division of Transplant Surgery (G.H., G.M.P.), Medical College of Wisconsin, Milwaukee, and Genzyme Corporation, Boston, Mass (S.L.).
Correspondence to Ashwani K. Khanna, PhD, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226. E-mail akkhanna{at}mcw.edu
Received June 9, 2004; revision received July 29, 2004; accepted August 11, 2004.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Long-term treatment of cardiac transplant recipients with cyclosporine results in a progressive decline in kidney function in a large number of patients. This complication is one of the most important prognostic parameters that determine the outcome of cardiac transplantation. Transforming growth factor-ß (TGF-ß) is one of the most potent mediators of the fibrogenic effects of cyclosporine.
Methods and Results— With the use of an experimental rodent model, heterotopic heart transplantation was performed, creating histocompatibility-disparate allografts. Because TGF-ß in part mediates both the immunosuppressive and nephrotoxic effects of cyclosporine, recipients were treated with cyclosporine with and without anti–TGF-ß antibody to determine whether anti–TGF-ß antibody could reduce the nephrotoxic effects of cyclosporine. Intrarenal expression of TGF-ß, collagen, fibronectin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-2 was studied with the use of reverse transcription–polymerase chain reaction. Intrarenal expression of TGF-ß protein was studied by immunohistochemistry and with the use of ELISA to quantify circulating levels of TGF-ß protein in plasma. Cyclosporine-induced graft survival (immunosuppressive effect) was abrogated with a higher concentration (2.5 mg/kg) of anti–TGF-ß antibody, whereas a lower concentration (1 mg/kg) inhibited both cyclosporine-induced expression of fibrogenic molecules and renal toxicity.
Conclusions— These results provide credence to the pivotal role of TGF-ß in immunosuppression-associated renal toxicity in recipients of cardiac transplantation. Furthermore, these findings support a potentially significant therapeutic use of optimal concentration of anti–TGF-ß antibody to ameliorate cyclosporine-associated nephrotoxicity in cardiac transplant recipients.
Key Words: transplantation • coronary disease • kidney • transforming growth factors
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The occurrence of chronic renal failure after cardiac transplantation is a major risk factor, and the 5-year risk is
7%.1 A number of clinical studies2–9 suggest that one of the common clinical complications after heart transplantation is chronic cyclosporine-induced nephrotoxicity, which generally leads to progressive renal failure.10 Van Gelder et al11 demonstrated that a significant rise in serum creatinine was found in cases compared with controls as early as 3 months after transplantation. Cyclosporine remains the central immunosuppressive agent for cardiac allograft recipients, even though its use leads to a greater than one-third decrease in creatinine clearance by 6 months after transplantation with progression to end-stage renal failure, requiring hemodialysis in 6.5% of cardiac transplant recipients. End-stage kidney disease may develop in 1% to 3% of cyclosporine-treated heart transplant recipients, and most patients show a decreased glomerular filtration rate.12 Recently, English et al13 compared the effect of tacrolimus and cyclosporine on nephrotoxic effects in pediatric cardiac transplant recipients and observed similar nephrotoxicity of both immunosuppressants. These findings demonstrate the need for a better strategy utilizing alternative or adjunctive agents that would allow decreased dosing as a means to achieve reduced nephrotoxicity of cyclosporine and other immunosuppressive agents while maintaining equivalent rates of graft survival. We performed studies in an established rat cardiac transplantation model to define the causal mechanism behind cyclosporine-mediated nephrotoxicity.14 The results demonstrated a significant increase in intrarenal expression of transforming growth factor-ß (TGF-ß) and profibrogenic genes in cardiac transplant recipients treated with cyclosporine for 120 days compared with isograft controls. Earlier, in a nontransplantation experimental model, we demonstrated that TGF-ß mediates at least some of the immunosuppression of cyclosporine and is nephrotoxic itself.15,16 In this study we explored the effects of anti–TGF-ß antibody on immunosuppression (graft survival) and nephrotoxicity after long-term treatment with cyclosporine in a rat heart transplantation model. This experimental model employs completely mismatched strains, and the allograft survival requires treatment with cyclosporine or other immunosuppressant therapy. Recipients were treated with cyclosporine alone or along with different concentrations of either anti–TGF-ß antibody or control antibody to study their effects on the intrarenal expression of TGF-ß, collagen, fibronectin, matrix metalloproteinase-2 (MMP-2), and tissue inhibitor of metalloproteinase-2 (TIMP-2). We also studied intrarenal expression of TGF-ß protein and circulating levels of plasma TGF-ß protein. Samples of renal tissue and plasma from rats treated with cyclosporine alone or with either anti–TGF-ß antibody or control antibody therapy were compared with like samples from animals receiving isografts with no immunosuppression therapy. We also compared the renal histopathological changes in these groups.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Experimental Groups, Preparation, and Transplantation
This study was divided into 6 groups (n=6 in each) including the following: untreated control; cyclosporine; cyclosporine plus 2.5 mg/kg control antibody; cyclosporine plus 2.5 mg/kg anti–TGF-ß antibody; cyclosporine plus 1.0 mg/kg anti–TGF-ß antibody; and isograft controls. Heterotopic heart transplantations were performed on the entire study population with the use of rat strains Wistar Furth and Lewis as donors and recipients, respectively, as described by us.17 Donor rats were heparinized (1000 U IP) and anesthetized with sodium pentobarbital (50 mg/kg IP). An abdominal incision was made and extended from the thoracic cavity, and the chest wall was removed. Blunt dissection of the heart, aorta, and pulmonary artery was performed. The pulmonary veins and inferior vena cava were ligated, and the graft was excised and placed in iced physiological saline. Recipient rats were then anesthetized with sodium pentobarbital (50 mg/kg IP). A midline laparotomy was performed. The abdominal aorta and vena cava were dissected and clamped with straight vascular clamps to prevent bleeding. A longitudinal aortotomy and venotomy approximately 5 mm in length was performed. With the use of standard microvascular techniques with 8-0 proline suture, end-to-side anastomoses of the aorta to the abdominal aorta and pulmonary artery to the inferior vena cava were made. Hemostasis was achieved, and the incision was closed with a 3-0 Vicryl suture.
Animal Monitoring, Euthanasia, and Tissue Harvesting
Rats were monitored daily for evidence of allograft slowing and failure. They were then anesthetized with sodium pentobarbital (50 mg/kg IP). Animals were exsanguinated via a native heart intraventricular puncture. Plasma samples were assayed for TGF-ß protein with the use of a specific ELISA kit. Both kidneys were obtained (one for gene expression and one for histology and immunohistochemistry).
Immunosuppression Protocols
Immunosuppression was accomplished with the use of cyclosporine in the appropriate groups. Cyclosporine was used at a dosage of 2.5 mg/kg IM for the duration of the experiment with and without anti–TGF-ß or control antibody. Treatment of anti–TGF-ß antibody or control antibody was administered by intraperitoneal injection every third day until the time of euthanasia or organ rejection.
1D11 is a murine monoclonal antibody (IgG1) that specifically neutralizes the biological activity of TGF-ß1, TGF-ß2, and TGF-ß3. The antibody recognizes active and not latent TGF-ß. The control antibody (13C4) is also a murine monoclonal antibody (IgG1) that specifically binds shigella toxin. Both antibodies were produced and purified at Genzyme Corporation. Antibodies were determined to be free of detectable endotoxin.
Measurement of TGF-ß Protein in Rat Plasma
TGF-ß1 protein was measured as previously described.15 Plasma from rats was separated and stored at –70°C. TGF-ß1 protein was assayed on acid-activated samples by a sandwich ELISA with the use of a commercial TGF-ß1–specific kit (Promega).
Histopathology and Immunohistochemistry for TGF-ß1 Protein Expression in Kidney Tissues
One kidney from each animal was fixed in formalin and paraffin imbedded. We used hematoxylin-eosin and Masson’s trichrome staining to assess histological changes. TGF-ß was identified with the use of immunohistochemistry.14 Formalin-fixed, paraffin-embedded tissues were sectioned at 5 µm, deparaffinized in xylene, and rehydrated in graded ethanol to PBS. After endogenous peroxidase activity was blocked with methanol/peroxide (18:1 vol/vol) for 30 minutes, nonspecific binding was blocked for 1 hour with 1.5% avidin/biotin diluted in PBS supplemented with 10% normal horse serum and 3% BSA. The tissue sections were then incubated overnight at 4°C with 1D11 monoclonal antibody (50 mg/mL) in the aforementioned PBS. After multiple washings with PBS, the slides were incubated for 1 hour with 1:1000 diluted biotin-labeled anti-mouse IgG horse anti-serum at room temperature, then washed again extensively in PBS and then in the ABC solution for 30 minutes. The slides were then developed for 10 minutes in diaminobenzidine and rinsed with water for 10 minutes. The slides were then counterstained with hematoxylin followed by dehydration in graded ethanol and xylene. The slides were mounted with Permount for evaluation. Samples from each group were graded for histopathological changes and immunohistochemistry staining. The intensity of immunostaining was graded from 0 (no staining) to 4+ (maximum staining).
Detection of mRNA by Reverse Transcription and Polymerase Chain Reaction in Kidney Tissues
Total RNA was isolated from a small piece of kidney tissue from rats with the use of SV Total RNA Isolation System (Promega), and quality of RNA was verified by 260/280-nm ratio. Then 1 µg of RNA was reverse transcribed to cDNA with the use of Superscript First Strand Synthesis System for reverse transcription–polymerase chain reaction (RT-PCR) (Life Technologies). The amplification by PCR was performed with the use of 1 µL of cDNA and 2 µL each of 2.5 mmol/L coding and noncoding oligonucleotide primers and Platinum PCR Supermix (Life Technologies). The primer sequences were as follows: TGF-ß1: coding 5'-ACG CCT GAG TGG CTG TCT TTT-3' and noncoding 5'-ACG TGG AGT TTG TTA TCT TTG-3'18; ß-actin: coding 5'-GAT CTG GCA CCA CAC CTT CTA-3' and noncoding 5'-GCA GGA TGG CGT GAG GGA GAG-3'19; collagen I: coding 5'-CCC ACG TAG GTG TCC TAA AGT-3' and noncoding 5'-CCG TGG TGCTAAAATAATAAA-3'20; fibronectin: coding 5'-ATG ATG AGG TGC ACG TGT GT-3' and noncoding 5'-GAT GGG GTC ACA TTT CCA TC-3'21; MMP-2: coding 5'-GTG CTG AAG GAC ACA CTA AA-3' and noncoding 5'-TTG CCA TCC TTC TTT TCA AA-3'22; TIMP-2: coding 5'-AAA CGA CAC TTA TGG CAA AC-3' and noncoding 5'-ACA GGA AGC GTC ACT TCT CT-3'.23 For this semiquantitative estimation of gene expression, we performed cycle analysis for each primer pair to determine the cycle number for optimal amplification. The PCR products were resolved in 1% agarose gel electrophoresis. Ethidium bromide–stained specific bands were visualized under UV light and photographed. The densitometric analysis of the specific bands was made with the use of Alpha-Imager (Alpha Innotech Corp), and data are represented as the ratio of the specific gene to ß-actin.
Data Analysis
Data are expressed as mean±SEM. Differences between appropriate groups were then analyzed by ANOVA.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Effect of Anti–TGF-ß Antibody on Immunosuppressive Effects of Cyclosporine
The rat heterotopic heart transplantation model employing the completely mismatched strain combination Wistar Furth (WF) (RTIu) into Lewis (LEW) (RTIl), which was used in these studies, requires chronic immunosuppression to prevent rejection. We administered a TGF-ß–neutralizing antibody or an isotype-matched control antibody to determine whether TGF-ß expression affects allograft survival in cyclosporine-treated animals within the first 30 days.
Grafts from untreated animals were rejected on average 11 days after transplantation (n=6; 11±1.5 days). In contrast, grafts from cyclosporine-treated animals survived for an average of 117 days (n=6; 117±9 days; P<0.001). To better understand the role of TGF-ß in the pathogenesis of chronic rejection, heart transplant recipients were dosed with 1.0 or 2.5 mg/kg of anti–TGF-ß antibody 3 times weekly beginning at 3 days after transplantation. Control antibody was administered at an identical concentration and dosing schedule. No differences in survival were observed between the groups with untreated allografts and cyclosporine plus 2.5 mg/kg anti–TGF-ß antibody (Figure 1). Animals in the cyclosporine plus 2.5 mg/kg control antibody group did not experience rejection but were euthanized on similar days as animals treated with cyclosporine plus anti–TGF-ß antibody to compare histological changes (not shown).
|
In sharp contrast, the animals that were injected with 1.0 mg/kg of antibody did not experience rejection in the same manner as animals that received cyclosporine plus 2.5 mg/kg of anti–TGF-ß antibody, and the mean survival time was 99±8 days. This was highly significant compared with the higher-dose antibody group (P<0.01). The data strongly support our hypothesis that the immunosuppressive effects of cyclosporine are mediated by TGF-ß because anti–TGF-ß at a concentration of 2.5 mg/kg totally abolished the efficacy of cyclosporine. We also hypothesized that rats injected with a lower dose of anti–TGF-ß antibody could have less severe renal pathological changes because the fibrogenic properties of TGF-ß would be neutralized by anti–TGF-ß antibody, and the current data support this. We have analyzed the mRNA expression of different profibrotic genes in renal tissues and the histopathological analysis of renal tissues from recipients treated with cyclosporine, cyclosporine plus control antibody, and cyclosporine plus anti–TGF-ß antibody.
Effect of Anti–TGF-ß Antibody on Nephrotoxic Effects of Cyclosporine
These experiments were performed to study the role of TGF-ß in nephrotoxic effects of cyclosporine. Along with cyclosporine, recipients were also treated with TGF-ß or control antibody (1.0 mg/kg) 3 times per week until the time of rejection. Groups included the following: untreated allografts; cyclosporine-treated allografts; cyclosporine plus control antibody (1.0 mg/kg)–treated allografts; cyclosporine plus anti–TGF-ß antibody (1.0 mg/kg)–treated allografts; and isograft controls.
Renal Function
Renal function was measured by quantifying creatinine and blood urea nitrogen {BUN) levels in plasma of rats obtained after euthanasia from all experimental animals studied. Quantification was performed with the use of kits from Sigma. BUN levels were elevated in the cyclosporine-treated animals versus isografts (18.6±0.85 versus 12.6±0.4 mg/dL; P<0.0001), and decreased levels were observed in cyclosporine plus anti–TGF-ß antibody–treated animals (13.8±0.63 mg/dL; P<0.03) but not with cyclosporine plus control antibody–treated animals (17.8±0.45 mg/dL). A significant increase in serum creatinine (0.75±0.03 versus 0.43±0.2 mg/dL; P<0.0001) was observed in cyclosporine-treated recipients compared with isografts. Similar to BUN levels, animals treated with cyclosporine plus anti–TGF-ß antibody (0.49±0.06 mg/dL; P<0.003) but not control antibody (0.68±0.08 mg/dL) exhibited decreased creatinine levels.
Intrarenal Expression of TGF-ß, Collagen, and Fibronectin mRNA
The results in Figure 2, expressed as gene/ß-actin ratio (n=6 each), demonstrate the effect of long-term treatment of cyclosporine with and without anti–TGF-ß or control antibody on intrarenal mRNA expression of TGF-ß1, collagen, and fibronectin. For TGF-ß, long-term treatment of cyclosporine resulted in increased intrarenal expression of TGF-ß mRNA (P<0.01) compared with isografts. There was no difference (P=0.12) in TGF-ß mRNA expression between isografts and recipients treated with cyclosporine plus anti–TGF-ß antibody (1.0 mg/kg), whereas a significant difference (P<0.003) was observed between cyclosporine-treated and cyclosporine plus anti–TGF-ß antibody (2.5 mg/kg)–treated recipients. No difference was observed between cyclosporine-treated and cyclosporine plus control antibody–treated recipients. For collagen, long-term treatment of cyclosporine resulted in increased intrarenal expression of collagen mRNA (P<0.0001) compared with isografts. There was a significant difference (P<0.008) observed between cyclosporine-treated and cyclosporine plus anti–TGF-ß antibody–treated recipients (Figure 2). No difference was observed between cyclosporine-treated and cyclosporine plus control antibody–treated recipients. Similar results were obtained with fibronectin mRNA (Figure 2); long-term treatment of cyclosporine resulted in increased intrarenal expression of fibronectin mRNA (P<0.0001) compared with isografts. A significant difference (P<0.002) was observed between cyclosporine-treated and cyclosporine plus anti–TGF-ß antibody–treated recipients. No difference was observed between cyclosporine-treated and cyclosporine plus control antibody–treated recipients.
|
Intrarenal Expression of MMP-2 and TIMP-2
The results shown in Figure 3 demonstrate that long-term treatment with cyclosporine resulted in increased intrarenal expression of MMP-2 mRNA (P<0.0002) compared with isografts. A significant difference (P<0.004) was observed between cyclosporine-treated and cyclosporine plus anti–TGF-ß antibody–treated recipients. No difference was observed between cyclosporine-treated and cyclosporine plus control antibody–treated recipients. Unlike other genes, anti–TGF-ß antibody–treated recipients demonstrated reduced but not statistically different intrarenal expression of TIMP-2 mRNA. No difference was observed between cyclosporine-treated and cyclosporine plus control antibody–treated recipients.
|
Effect of Anti–TGF-ß Antibody on Circulating Levels of TGF-ß Protein
The results shown in Figure 4 demonstrate that compared with isografts, long-term treatment with cyclosporine resulted in a significant (P<0.0001) increase in circulating levels of TGF-ß protein. There was no difference in TGF-ß levels among isografts and cyclosporine plus control antibody–treated recipients; however, a statistically significant difference (P<0.003) was observed between cyclosporine-treated and cyclosporine plus anti–TGF-ß antibody–treated recipients.
|
Effect of Anti–TGF-ß Antibody on Intrarenal Expression of TGF-ß Protein
The results shown in Figure 5 demonstrate a significantly higher (3+ to 4+) staining of intrarenal TGF-ß protein expression in cyclosporine-treated recipients that was not different in control antibody plus cyclosporine–treated recipients. TGF-ß protein staining in animals treated with cyclosporine plus 1.0 mg/kg anti–TGF-ß antibody was reduced; however, it was slightly higher than in the isograft group.
|
Effect of Anti–TGF-ß Antibody on Renal Histology
Treatment with cyclosporine resulted in histopathological changes similar to those in patients receiving long-term treatment with cyclosporine. Histopathological analysis of periodic acid–Schiff (PAS)– and hematoxylin-eosin–stained slides from renal tissues of cardiac transplant recipient rats treated with (1) cyclosporine alone, (2) cyclosporine plus control antibody, and (3) cyclosporine plus anti–TGF-ß antibody (1.0 mg/kg) was performed. Tubular vacuolization and vascular changes, including increased PAS staining of vascular structures, were found in cyclosporine-treated and cyclosporine plus control antibody–treated animals. Interestingly, although not completely normal, these changes were either not observed or only randomly observed and were not prominent in cyclosporine plus anti–TGFß antibody–treated animals. Of particular note, PAS staining was also diminished in anti–TGF-ß–treated recipients (Figure 6).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Our earlier studies14–16 focused on the potential role of TGF-ß in the pathogenesis of cyclosporine-induced nephrotoxicity. In this study we extend our previous investigation to examine the effect of a TGF-ß antibody in a cardiac transplantation model. We show for the first time that it is possible to separate the immunosuppressive and nephrotoxic effects of cyclosporine, which we attribute to upregulated TGF-ß, in organ transplantation. TGF-ß is a potent immunosuppressant,24 and it was not surprising that a neutralizing antibody could reduce the therapeutic efficacy of cyclosporine. However, it was surprising that the fibrogenic properties of cyclosporine were abrogated on 2.5-fold lower dosing without compromise to the immunosuppressive activity. Importantly, these data demonstrate that optimal dosing with a TGF-ß antagonist can discriminate the nephrotoxic and immunosuppressive activities of cyclosporine, and this discovery may have clinical utility. Clearly, further dose-response studies are necessary to better understand the dose-efficacy relationship.
Although the present results are directed at an understanding of cyclosporine nephrotoxicity, our previous studies15,25–29 also demonstrate that TGF-ß participates in both the immunosuppressive and nephrotoxic effects of tacrolimus and sirolimus. It is not known whether adjunctive therapy with a TGF-ß–neutralizing agent would also reduce the nephrotoxic effects of these 2 immunosuppressants. A number of experimental strategies have been examined for the purpose of reducing nephrotoxicity while retaining immunosuppression in this class of drugs. In many instances, the adjunctive therapies are thought to work by inhibiting the expression or activity of TGF-ß. For example, Shihab et al30 concluded from their studies that the beneficial effect of mycophenolate mofetil was likely due to its inhibition of TGF-ß expression. Other agents that may moderate this nephrotoxicity by a TGF-ß–related mechanism include spironolactone,31 losartan,32 vitamin E,33 pirfenidone,34 and angiotensin receptor blockade.35
A number of studies have implicated TGF-ß as a key mediator of cyclosporine-induced nephrotoxicity, but definitive evidence has only recently been reported. Our laboratory15 and those of others36,37 have examined the effects of administering TGF-ß–neutralizing antibodies to nontransplantation models of cyclosporine nephrotoxicity. These studies have shown that blocking TGF-ß can normalize the expression of collagen types III and I and substantially reduce overall tissue fibrosis when examined histologically. The effects of TGF-ß–neutralizing antibodies were not limited to reduction in fibrosis but also showed protection of tubular epithelial cells and reduction in markers of tissue hypoxia. Finally, these studies also demonstrated reduction in the expression of TGF-ß isoforms, which is likely to interrupt the positive feedback loop that is known to regulate TGF-ß production.
In this study, however, we examined the effect of administering a TGF-ß–neutralizing antibody in a rat cardiac transplantation model. A direct effect of TGF-ß inhibition on immunosuppression-induced nephrotoxicity in an organ transplantation model has not been attempted previously. The results from the present study demonstrate that treating recipients of cardiac transplants with cyclosporine plus 2.5 mg/kg of anti–TGF-ß antibody reduces the immunosuppressive effects of cyclosporine. In contrast, a lower dose of antibody combined with cyclosporine resulted in prolonged survival and decreased expression of fibrogenic genes, including TGF-ß mRNA. These data provide evidence that TGF-ß is a direct mediator of cyclosporine-induced nephrotoxic effects in recipients of cardiac transplantation.
These studies are significant because numerous clinical studies have confirmed that long-term treatment of cardiac transplantation patients with cyclosporine is associated with severe nephrotoxicity.2–9 Van Gelder et al11 noted that end-stage renal disease occurred in 8% of heart transplant recipients treated with cyclosporine. Goldstein et al12 observed that 6.5% of patients developed end-stage renal failure. Tinawi et al38 documented a sequential increase in serum creatinine levels in cardiac transplant recipients. Griffiths et al39 also observed severe renal histopathological changes in heart transplant recipients treated with cyclosporine, with tubular atrophy being the most prominently observed feature; earlier, Falkenhain et al4 demonstrated that the renal damage increased in relation to the time of exposure and dose of cyclosporine.
On the basis of the documented role of MMP-2 and TIMP-2 in renal damage,40–45 we compared the intrarenal expression of MMP-2 and TIMP-2 mRNA in kidney tissues of rat heart transplant recipients treated with cyclosporine versus cyclosporine plus anti–TGF-ß antibody and isograft controls. Our results documented that the expression of MMP-2 was significantly increased in renal tissues from rats treated with cyclosporine compared with recipients treated with cyclosporine plus anti–TGF-ß antibody and isograft controls. These results demonstrate that the increased expression of MMP-2 is associated with the nephrotoxic effects of cyclosporine in a rat cardiac transplantation model. Interestingly, TGF-ß, like collagen and fibronectin, is known to induce the expression of MMP-2. This increased expression of MMP-2 was also observed in a nontransplantation rat model studying the mechanism of the nephrotoxic effects of cyclosporine, which correlated with increased expression of TGF-ß. Anti–TGF-ß antibody treatment in cyclosporine-treated rats significantly reduced collagen TGF-ß, collagen, and fibronectin mRNA levels.15 These results support the findings of this study. The results of this study also demonstrate that the expression of TIMP-2 was significantly higher in cyclosporine-treated recipients than in cyclosporine plus anti–TGF-ß antibody–treated recipients and isograft controls. Increased expression of MMP-2 and TIMP-2 has been noted in other clinical and experimental models of tissue fibrosis; the critical component is a persistent increase in both molecules, signaling increased fibrosis, and the ratio of TIMP-2 and MMP-2 may be a better indicator of the precise role of these tissue repair molecules in nephrotoxicity/fibrosis.
Additionally, our results uniquely demonstrate that intrarenal expression of TGF-ß protein was increased in cyclosporine-treated recipients compared with isografts. The treatment of the recipients with cyclosporine plus anti–TGF-ß antibody, but not control antibody, inhibited intrarenal TGF-ß protein expression. Furthermore, renal histological changes similar to those observed during clinical cyclosporine nephrotoxicity were observed in cyclosporine-treated recipients and were significantly reversed by anti–TGF-ß antibody treatment but not with control antibody.
The results from this study demonstrate the feasibility of anti–TGF-ß antibody as a therapeutic strategy to limit the nephrotoxic effects of long-term treatment with cyclosporine in organ transplantation. However, similar to these experiments, a detailed study with dose effects of antibody needs to be performed. Furthermore, by in vitro, in vivo, and clinical studies, we have demonstrated induction of TGF-ß with other immunosuppressive agents such as tacrolimus and sirolimus.25–29 Therefore, it is attractive to hypothesize that anti–TGF-ß antibody may provide similar benefits to counteract adverse nephrotoxic effects observed with long-term use of these drugs as well.
In summary, these new data demonstrate that long-term treatment of rat heart transplant recipients with cyclosporine results not only in histological change and renal function change but also in significantly increased expression of profibrogenic genes. The interesting findings with clinical relevance are inhibition of TGF-ß protein, mRNA, and other fibrogenic genes; improvement in renal function; and histological alteration with concomitant use of anti–TGF-ß antibody with cyclosporine. These results provide strong evidence for the promising therapeutic application of anti–TGF-ß antibody to prevent nephrotoxicity. This may have clinical relevance in organ transplantation and other diseases, including diabetic nephropathy.
|
Acknowledgments |
|---|
This work was supported in part by National Institutes of Health grants AI41703 (to Dr Khanna) and HL64637 (to Dr Pieper). Dr Khanna also thanks Seema Sernovitz for editorial help.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003; 349: 931–940.
2. Woolfson RG, Neild GH. Cyclosporine nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant. 1997; 12: 2054–2056.
3. Jayasena SD, Riaz A, Lewis CM, Neild GH, Thompson FD, Woolfson R. Outcome in patients with end-stage renal disease following heart or heart-lung transplantation receiving peritoneal dialysis. Nephrol Dial Transplant. 2001; 16: 1681–1685.
4. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation. 1996; 62: 364–370.[CrossRef][Medline] [Order article via Infotrieve]
5. Lewis RM, Verani RR, Vo C, Katz SM, Van Buren CT, Radovancevic B, Kerman RH, Frazier OH, Kahan BD. Evaluation of chronic renal disease in heart transplant recipients: importance of pretransplantation native kidney histologic evaluation. J Heart Lung Transplant. 1994; 13: 376–380.[Medline] [Order article via Infotrieve]
6. Nizze H, Mihatsch MJ, Zollinger HU, Brocheriou C, Gokel JM, Henry K, Sloane JP, Stovin PG. Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants. Clin Nephrol. 1988; 30: 248–260.[Medline] [Order article via Infotrieve]
7. Greenberg A, Egel JW, Thompson ME, Hardesty RL, Griffith BP, Bahnson HT, Bernstein RL, Hastillo A, Hess ML, Puschett JB. Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. Am J Kidney Dis. 1987; 9: 12–22.[Medline] [Order article via Infotrieve]
8. Chomette G, Auriol M, Beaufils H, Rottemburg J, Cabrol C. Morphology of cyclosporine nephrotoxicity in human heart transplant recipients. J Heart Transplant. 1986; 5: 273–278.[Medline] [Order article via Infotrieve]
9. Goldstein J, Thoua Y, Wellens F, Leclerc JL, Vanherweghem JL, Vereerstraeten P, Primo G, Toussaint C. Cyclosporine nephropathy after heart and heart-lung transplantation. Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985; 21: 973–981.[Medline] [Order article via Infotrieve]
10. Campistol JM, Inigo P, Larios S, Bescos M, Oppenheimer F. Role of transforming growth factor-ß(1) in the progression of chronic allograft nephropathy. Nephrol Dial Transplant. 2001; 16 (suppl 1): 114–116.
11. van Gelder T, Balk AH, Zietse R, Hesse C, Mochtar B, Weimar W. Renal insufficiency after heart transplantation: a case-control study. Nephrol Dial Transplant. 1998; 13: 2322–2326.
12. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation. 1997; 63: 664–668.[CrossRef][Medline] [Order article via Infotrieve]
13. English RF, Pophal SA, Bacanu SA, Fricker J, Boyle GJ, Ellis D, Harker K, Sutton R, Miller SA, Law YM, Pigula FA, Webber SA. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. Am J Transplant. 2002; 2: 769–773.[CrossRef][Medline] [Order article via Infotrieve]
14. Khanna A, Hosenpud JS, Plummer MS, Hosenpud JD. Analysis of TGF-ß and pro-fibrogenic molecules in a rat cardiac allograft model treated with cyclosporine. Transplantation. 2002; 73: 1543–1549.[CrossRef][Medline] [Order article via Infotrieve]
15. Khanna AK, Cairns VR, Becker CG, Hosenpud JD. Transforming growth factor (TGF)-ß mimics and anti-TGFß antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-ß in immunosuppression and nephrotoxicity of cyclosporine. Transplantation. 1999; 67: 882–889.[CrossRef][Medline] [Order article via Infotrieve]
16. Khanna AK, Li B, Sehajpal PK, Sharma VK, Suthanthiran M. Mechanism of action of cyclosporine: a new hypothesis implicating transforming growth factor-ß. Transplant Rev. 1995; 9: 41–48.
17. Hosenpud JD, Boyle TM, Hensler H, Sanford G, Khanna AK. The relationship between acute rejection and chronic rejection is highly dependent on specific MHC matching: a multi-strain rat heterotopic heart transplant study. Transplantation. 2000; 69: 2173–2178.[CrossRef][Medline] [Order article via Infotrieve]
18. Qian SW, Kondaiah P, Roberts AB, Sporn MB. cDNA cloning by PCR of rat transforming growth factor ß-1. Nucleic Acid Res. 1990; 18: 3059.
19. Ponte P, Ng SY, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human ß-actin cDNA. Nucleic Acids Res. 1984; 12: 1687.
20. Frankel FR, Hsu C-YJ, Meyers JC, Lin E, Lyttle CR, Komm B, Mohn K. Regulation of 
-2-(I), -1-(III), and -2-(IV) collagen mRNAs by estradiol in the immature rat uterus. DNA. 1988; 7: 347–354.[Medline]
[Order article via Infotrieve]
21. Schwarzbauer JE, Patel RS, Fonda D, Hynes RO. Multiple sites of alternative splicing of the rat fibronectin gene transcript. EMBO J. 1987; 6: 2573–2580.[Medline] [Order article via Infotrieve]
22. Harendza S, Pollock AS, Mertens PR, Lovett DH. Tissue-specific enhancer-promoter interactions regulate high level constitutive expression of matrix metalloproteinase 2 by glomerular mesangial cells J. Biol Chem. 1995; 270: 18786–18796.
23. Santoro M, Battaglia C, Zhang L, Carlomagno F, Martelli ML, Salvatore D, Fusco A. Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. Exp Cell Res. 1994; 213: 398–403.[CrossRef][Medline] [Order article via Infotrieve]
24. Lucas C, Wallick S, Fendly BM, Figari I, Palladino MA. TGF-beta: a possible autocrine immune regulator. Ciba Found Symp. 1991; 157: 98–108.[Medline] [Order article via Infotrieve]
25. Khanna A, Cairns V, Hosenpud JD. Tacrolimus induces increased expression of transforming growth factor-beta in lymphoid and non-lymphoid cells. Transplantation. 1999; 67: 614–619.[CrossRef][Medline] [Order article via Infotrieve]
26. Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation. 2000; 70: 690–694.[CrossRef][Medline] [Order article via Infotrieve]
27. Khanna A, Plummer M, Bromberek C, Woodliff J, Hariharan S. Immunomodulation in stable renal transplant recipients with concomitant tacrolimus and sirolimus therapy. BMC Med Immunol. 2002; 1: 3–9.
28. Khanna A, Cairns V, Becker CG, Hosenpud JD. TGF-beta: a link between immunosuppression, nephrotoxicity and CsA. Transplant Proc. 1998; 30: 944–945.[CrossRef][Medline] [Order article via Infotrieve]
29. Khanna AK, Plummer M, Bromberek C, Bresnahan B, Hariharan S. Expression of TGF-ß and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int. 2002; 62: 2257–2263.[CrossRef][Medline] [Order article via Infotrieve]
30. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity. Am J Transplant. 2003; 3: 1550–1559.[CrossRef][Medline] [Order article via Infotrieve]
31. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, Garcia-Torres R, Lopez-Casillas F, Gamba G, Bobadilla NA. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int. 2003; 63: 43–52.[Medline] [Order article via Infotrieve]
32. Yang CW, Ahn HJ, Kim WY, Li C, Jung JY, Yoon SA, Kim YS, Cha JH, Kim J, Bang BK. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation. 2003; 75: 309–315.[CrossRef][Medline] [Order article via Infotrieve]
33. Jenkins JK, Huang H, Ndebele K, Salahudeen AK. Vitamin E inhibits renal mRNA expression of COX II, HO I, TGF-beta, and osteopontin in the rat model of cyclosporine nephrotoxicity. Transplantation. 2001; 71: 331–334.[CrossRef][Medline] [Order article via Infotrieve]
34. Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant. 2002; 2: 111–119.[CrossRef][Medline] [Order article via Infotrieve]
35. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol. 2003; 14: 1132–1144.
36. Islam M, Burke JF Jr, McGowan TA, Zhu Y, Dunn SR, McCue P, Kanalas J, Sharma K. Effect of anti-transforming growth factor-ß antibodies in cyclosporine-induced renal dysfunction. Kidney Int. 2001; 59: 498–506.[CrossRef][Medline] [Order article via Infotrieve]
37. Ling H, Li X, Jha S, Wang W, Karetskaya L, Pratt B, Ledbetter S. Therapeutic role of TGF-(ß)–neutralizing antibody in mouse cyclosporine nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol. 2003; 14: 377–388.
38. Tinawi M, Miller L, Bastani B. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center. Clin Transplant. 1997; 11: 1–8.[Medline] [Order article via Infotrieve]
39. Griffiths MH, Crowe AV, Papadaki L, Banner NR, Yacoub MH, Thompson FD, Neild GH. Cyclosporin nephrotoxicity in heart and lung transplant patients. QJM. 1996; 10: 751–763.
40. Ignotz RA, Endo T, Massague J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-ß. J Biol Chem. 1987; 262: 6443–6446.
41. Stokes MB, Hudkins KL, Zaharia V, Taneda S, Alpers CE. Up-regulation of extracellular matrix proteoglycans and collagen type I in human crescentic glomerulonephritis. Kidney Int. 2001; 59: 532–542.[CrossRef][Medline] [Order article via Infotrieve]
42. Lelongt B, Legallicier B, Piedagnel R, Ronco PM. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? Curr Opin Nephrol Hypertens. 2001; 10: 7–12.[Medline] [Order article via Infotrieve]
43. Lelongt B, Trugnan G, Murphy G, Ronco PM. Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro. J Cell Biol. 1997; 136: 1363–1373.
44. Davies M, Martin J, Thomas GJ, Lovett DH. Proteinases and glomerular matrix turnover. Kidney Int. 1992; 41: 671–678.[Medline] [Order article via Infotrieve]
45. Akiyama K, Shikata K, Sugimoto H, Matsuda M, Shikata Y, Fujimoto N, Obata K, Matsui H, Makino H. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol. 1997; 95: 115–128.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. K. Khanna, J. Xu, P. A. Uber, A. P. Burke, C. Baquet, and M. R. Mehra Tobacco Smoke Exposure in Either the Donor or Recipient Before Transplantation Accelerates Cardiac Allograft Rejection, Vascular Inflammation, and Graft Loss Circulation, November 3, 2009; 120(18): 1814 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Harradine, K. Ridd, E. F. Saunier, F. F. Clermont, J. Perez-Losada, D. H. Moore, E. H. Epstein Jr., B. C. Bastian, and R. J. Akhurst Elevated Cutaneous Smad Activation Associates with Enhanced Skin Tumor Susceptibility in Organ Transplant Recipients Clin. Cancer Res., August 15, 2009; 15(16): 5101 - 5107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Pieper, I. A. Ionova, B. C. Cooley, R. Q. Migrino, A. K. Khanna, J. Whitsett, and J. Vasquez-Vivar Sepiapterin Decreases Acute Rejection and Apoptosis in Cardiac Transplants Independently of Changes in Nitric Oxide and Inducible Nitric-Oxide Synthase Dimerization J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 890 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Khanna and G. M. Pieper Reply Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2403 - 2403. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||